Kuwait Epilepsy Drugs Market Size & Outlook, 2025-2030
The epilepsy drugs market in Kuwait is expected to reach a projected revenue of US$ 11.1 million by 2030. A compound annual growth rate of 3.8% is expected of Kuwait epilepsy drugs market from 2025 to 2030.
Revenue, 2024 (US$M)
$8.8
Forecast, 2030 (US$M)
$11.1
CAGR, 2025 - 2030
3.8%
Report Coverage
Kuwait
Kuwait Epilepsy Drugs Market, 2018-2030 (US$M)
Global Market
Related Markets
Kuwait epilepsy drugs market highlights
- The Kuwait epilepsy drugs market generated a revenue of USD 8.8 million in 2024 and is expected to reach USD 11.1 million by 2030.
- The Kuwait market is expected to grow at a CAGR of 3.8% from 2025 to 2030.
- In terms of segment, first generation anti-epileptics was the largest revenue generating product in 2024.
- Second Generation Anti-epileptics is the most lucrative product segment registering the fastest growth during the forecast period.
Epilepsy drugs market data book summary
| Market revenue in 2024 | USD 8.8 million |
| Market revenue in 2030 | USD 11.1 million |
| Growth rate | 3.8% (CAGR from 2025 to 2030) |
| Largest segment | First generation anti-epileptics |
| Fastest growing segment | Second Generation Anti-epileptics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics |
| Key market players worldwide | UCB SA, Sanofi SA, Pfizer Inc, Otsuka Pharmaceutical, Eisai Co Ltd, Abbott Laboratories, Novartis AG ADR, GlaxoSmithKline, Sumitomo Pharma Co Ltd, Neurelis, Jazz Pharmaceuticals PLC |
Other key industry trends
- In terms of revenue, Kuwait accounted for 0.1% of the global epilepsy drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa epilepsy drugs market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 109.3 million by 2030.
No credit card required*
Publish Date: Jan 17, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Epilepsy Drugs Market
Epilepsy drugs market segmentation & scope
Epilepsy Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| UCB SA | View profile | 9,083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | www.ucb.com |
| Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | www.otsuka.co.jp/en/ |
| Eisai Co Ltd | View profile | 11,076 | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan, 112-8088 | www.eisai.co.jp |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | www.gsk.com |
| Neurelis | View profile | 101-250 | Encinitas, California, United States, North America | www.neurelis.com/ |
| Sumitomo Pharma Co Ltd | View profile | 6,250 | 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Japan, 541-0045 | www.sumitomo-pharma.com |
Kuwait epilepsy drugs market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Epilepsy Drugs Market Outlook will help companies and investors design strategic landscapes.
First Generation Anti-Epileptics was the largest segment with a revenue share of 42.05% in 2024.
Horizon Databook has segmented the Kuwait epilepsy drugs market based on first generation anti-epileptics, second generation anti-epileptics, third generation anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
- Kuwait Epilepsy Drugs Market Product Outlook (Revenue, USD Million , 2018-2030)
- First Generation Anti-epileptics
- Second Generation Anti-epileptics
- Third Generation Anti-epileptics
- Kuwait Epilepsy Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
Reasons to subscribe to epilepsy drugs market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of epilepsy drugs market databook
- Our clientele includes a mix of epilepsy drugs market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait epilepsy drugs market, including forecasts for subscribers. This country databook contains high-level insights into Kuwait epilepsy drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Kuwait Epilepsy Drugs Market, 2018-2030 (US$M)
Kuwait epilepsy drugs market statistics, by product, 2018-2030 (US$M)
